Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Videos|February 19, 2014
Validating the Link Between Obesity and Breast Inflammation in Women with Breast Cancer
Author(s)Neil M. Iyengar, MD
Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses a study presented at the 2013 San Antonio Breast Cancer Symposium that further validated the link between obesity and breast inflammation in women with breast cancer.
Advertisement
Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses a study presented at the 2013 San Antonio Breast Cancer Symposium that further validated the link between obesity and breast inflammation in women with breast cancer.
Clinical Pearls:
- A study that validated the link between obesity inflammation and aromatase activation was expanded
- The expanded cohort showed that breast inflammation correlated with body mass index and that breast inflammation of the fatty tissue occurs regardless of tumor phenotype
- The white adipose tissue from the abdominal fat of women who underwent breast reconstruction surgery was compared to the white adipose tissue from the breast
- Result showed that the majority of patients who had inflammation in one breast also had inflammation in the other breast or the abdominal fat pad
- As the abdominal fat pad seems to mirror the breast fat, the abdominal fat will be assessed because it is more easily obtained than the breast fat
Advertisement
Related to this article
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5